ATLANTA, Oct. 27, 2014 (GLOBE NEWSWIRE) -- PRGX Global, Inc. (Nasdaq:PRGX), the world's leading provider of accounts payable recovery audit services and the pioneer in Profit Discovery™, today announced its unaudited financial results for the third quarter and nine months ended September 30, 2014.

"While I am pleased that our global team delivered another quarter of sequential growth, increasing revenue 2.4% and Adjusted EBITDA 50% over the second quarter, these results fell below our expectations for profitability," said Ron Stewart, president and chief executive officer. "An area of improvement during the quarter was Recovery Audit Services – Americas, which compared to Q2 increased revenue by 5.6% and Adjusted EBITDA by 21.2%, respectively. Included in these results was our Contract Compliance business, which is now contributing to the top and bottom lines after our investment in the first half of the year."

"I am particularly encouraged by the favorable progress in Adjacent Services, which essentially broke even on an Adjusted EBITDA basis during the quarter, after losing over $1 million in the second quarter. We have several projects underway at top global retailers that leverage our unique data knowledge and insights to drive significant incremental value for our clients," continued Mr. Stewart.

"While we achieved growth in revenue and Adjusted EBITDA compared to the second quarter, we continue to work through this transitional year. We must remain diligent in managing costs and improving the profitability of our core business. To that end, we continue to make excellent progress in our technology initiatives to further differentiate our position in the market. Finally, our current efforts in the Oil & Gas industry are demonstrating the value of focused industry expansion and we look forward to continued growth in this segment," concluded Mr. Stewart.

Consolidated Results for the Three Months Ended September 30, 2014

Consolidated revenue for the third quarter of 2014 decreased 19.5% to $43.0 million compared to $53.4 million in the same prior year period. After adjusting for changes in foreign exchange rates, consolidated third quarter revenue in 2014 decreased 19.2% compared to the same period in 2013. As previously communicated, 2014 revenue has been negatively impacted by significantly reduced auditing in the Medicare RAC program and rate and scope changes at large clients in our core recovery audit business. Consolidated revenue for the third quarter of 2014 increased 2.4% compared to the second quarter of 2014.

Recovery Audit Services – Americas revenue for the third quarter of 2014 decreased 11.8% to $28.6 million compared to $32.4 million in the same period in the prior year. On a constant dollar basis, adjusted for changes in foreign exchange rates, Recovery Audit Services – Americas revenue for the third quarter of 2014 decreased by 10.7% compared to the same period in 2013. Most of this reduction is the result of the rate and scope reductions at several large clients.

Recovery Audit Services – Europe/Asia-Pacific revenue for the third quarter of 2014 decreased 10.8% to $10.7 million compared to $12.0 million in the same period in the prior year. On a constant dollar basis, adjusted for changes in foreign exchange rates, Recovery Audit Services – Europe/Asia-Pacific revenue for the third quarter of 2014 decreased by 11.7% compared to the same period in 2013. The prior year third quarter included additional revenue resulting from audit accelerations at multiple clients which did not repeat in 2014's third quarter.

Adjacent Services revenue was $3.6 million for both the third quarter of 2014 and the same period in the prior year. As part of our strategy to more closely align Adjacent Services to our core recovery audit business, on October 1 st we divested our Chicago consulting practice which had been included in the Adjacent Services results.

Healthcare Claims Recovery Audit Services revenue for the third quarter of 2014 was $0.1 million compared to $5.4 million in the same period in the prior year. This expected decrease in revenue was primarily attributable to the substantial reduction in auditing as part of the Medicare RAC program.

Total cost of revenue for the third quarter of 2014 was $28.7 million, or 66.7% of revenue, compared to $31.8 million, or 59.6% of revenue, in the same period last year. The 66.7% of revenue for the third quarter of 2014 was an improvement compared to the 71.3% of revenue in the second quarter of 2014. SG&A for the third quarter of 2014 was $10.5 million compared to $13.0 million in the same period last year, a decrease of $2.5 million. Excluding transformation severance and related expenses, the year over year decrease in SG&A expenses for the quarter was $2.9 million. Depreciation and amortization expenses were $2.3 million in the third quarter of 2014 compared to $3.2 million in the prior year third quarter.

Net loss for the third quarter of 2014 was $(0.2) million, or $(0.01) per basic and diluted share, compared to net income of $4.9 million, or $0.17 per basic share and $0.16 per diluted share, for the same period in 2013.

Adjusted EBITDA for the third quarter of 2014 was $5.6 million, which was a 50% improvement compared to second quarter 2014. However, compared to $10.8 million for the same period in 2013, third quarter 2014 Adjusted EBITDA declined $5.2 million, of which $3.1 million is attributable to Recovery Audit Services – Americas and $2.0 million is attributable to Healthcare Claims Recovery Audit Services. Third quarter 2014 Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization (EBITDA) excluding a charge of $1.4 million related to stock-based compensation, $0.4 million of transformation severance and related expenses, and $1.2 million of foreign currency losses on short-term intercompany balances. The comparable Adjusted EBITDA amount for the third quarter of 2013 excludes from EBITDA for such period a $1.3 million charge related to stock-based compensation, $0.2 million of transformation severance and related expenses, a $0.7 million charge for acquisition-related charges, and $0.6 million of foreign currency gains on short-term intercompany balances. Schedule 3 attached to this press release provides a reconciliation of net income (loss) to each of EBIT (earnings before interest and taxes), EBITDA and Adjusted EBITDA.

Consolidated Results for the Nine Months Ended September 30, 2014

Consolidated revenue for the nine months ended September 30, 2014 decreased 17.4% to $122.9 million compared to $148.7 million in the same prior year period. Changes in foreign exchange rates did not have a significant impact on the comparison of consolidated revenue for the nine month periods ended September 30, 2014 and 2013.

Recovery Audit Services – Americas revenue for the nine months ended September 30, 2014 decreased 8.7% to $80.4 million compared to $88.0 million in the same period in the prior year. On a constant dollar basis, adjusted for changes in foreign exchange rates, Recovery Audit Services – Americas revenue for the nine month period decreased by 7.4% compared to the same period in 2013.

Recovery Audit Services – Europe/Asia-Pacific revenue for the nine months ended September 30, 2014 decreased 3.0% to $32.8 million compared to $33.8 million in the same period in the prior year. On a constant dollar basis, adjusted for changes in foreign exchange rates, Recovery Audit Services – Europe/Asia-Pacific revenue for the nine month period decreased by 6.0% compared to the same period in 2013.

Adjacent Services revenue for the nine months ended September 30, 2014 was $8.2 million compared to $10.7 million in the same period in the prior year.

Healthcare Claims Recovery Audit Services revenue for the nine months ended September 30, 2014 was $1.6 million compared to $16.2 million in the same period in the prior year.

Total cost of revenue for the nine months ended September 30, 2014 was $87.5 million, a reduction of $8.4 million compared to $95.9 million in the same period in the prior year. As a percent of revenue, cost of revenue was 71.2% for the nine month period ended September 30, 2014, compared to 64.5% in the same period in the prior year. The largest portion of this margin erosion was due to the wind down of the Medicare RAC program, with the remainder due to the decline in revenue in the other segments, as well as our investment in our Contract Compliance services. SG&A for the nine months ended September 30, 2014 was $31.5 million compared to $35.2 million in the same period in the prior year, a decline of $3.7 million. Excluding transformation severance and related expenses, the year over year decrease in SG&A expenses for the nine month period was $6.1 million. Depreciation and amortization expenses were $7.4 million for the nine months ended September 30, 2014 compared to $9.9 million in the same period in the prior year.

Net loss for the nine months ended September 30, 2014 was $(5.4) million, or $(0.18) per basic and diluted share, compared to net income of $6.2 million, or $0.21 per basic and diluted share, in the same period in the prior year. Net cash provided by operating activities for the nine months ended September 30, 2014 was $7.1 million compared to $10.3 million in the same period in the prior year.

Adjusted EBITDA for the nine months ended September 30, 2014 was $9.9 million compared to $22.4 million of Adjusted EBITDA for the same period in 2013, a decline of $12.5 million, of which $6.7 million is attributable to Recovery Audit Services – Americas and $6.8 million is attributable to Healthcare Claims Recovery Audit Services. For the nine months ended September 30, 2014, Adjusted EBITDA was earnings before interest, taxes, depreciation and amortization (EBITDA) excluding a charge of $3.4 million related to stock-based compensation, $2.4 million of transformation severance and related expenses, a $0.2 million charge for acquisition-related charges, and $1.1 million of foreign currency losses on short-term intercompany balances. The comparable Adjusted EBITDA amount for the nine months ended September 30, 2013 excludes from EBITDA for such period a $3.8 million charge related to stock-based compensation, $0.8 million of transformation severance and related expenses, a $0.2 million charge for acquisition-related charges, and $0.1 million of foreign currency gains on short-term intercompany balances. Schedule 3 attached to this press release provides a reconciliation of net income (loss) to each of EBIT, EBITDA and Adjusted EBITDA.

Liquidity

At September 30, 2014, the Company had unrestricted cash and cash equivalents of $26.3 million, with $8.5 million held in the U.S. and the remainder held outside the U.S. The Company has no borrowings against its revolving credit facility and no debt outstanding.

Stock Repurchase Program

During the third quarter of 2014, the Company repurchased 1.4 million shares of its outstanding common stock for an aggregate cost of $9.0 million, completing the previously announced $20 million repurchase program. Since the February 2014 announcement of the Company's stock repurchase program, the Company has repurchased 3.1 million shares, or 10.4% of its common stock outstanding as of the date of the announcement. On October 24, 2014, the Company's Board of Directors approved a $20 million increase in the program and extended the duration of the program to December 31, 2015. As of October 24, 2014, the Company had 27.3 million shares of common stock outstanding.

Third Quarter Earnings Call

As previously announced, management will hold a conference call tomorrow morning at 8:30 AM (Eastern time) to discuss the Company's third quarter 2014 financial results. To access the conference call, listeners in the U.S. and Canada should dial (877) 755-7423 at least 5 minutes prior to the start of the conference. Listeners outside the U.S. and Canada should dial (678) 894-3069. To be admitted to the call, listeners should use passcode 20616341.

This teleconference will also be audiocast on the Internet at www.prgx.com (click on "Events & Presentations" under "Investors"). A replay of the audiocast will be available at the same location on www.prgx.com beginning approximately two hours after the conclusion of the live audiocast, extending through January 31, 2015. Please note that the Internet audiocast is "listen-only." Microsoft Windows Media Player is required to access the live audiocast and the replay and can be downloaded from www.microsoft.com/windows/mediaplayer.

About PRGX Global, Inc.

Headquartered in Atlanta, Georgia, PRGX Global, Inc. is the world's leading provider of accounts payable recovery audit services. With over 1,600 employees, the Company operates and serves clients in more than 30 countries and provides its services to over 75% of the top 20 global retailers. PRGX is also pioneering Profit Discovery, a unique combination of audit, analytics and advisory services that improves client financial performance. For additional information, please visit PRGX at www.prgx.com.

Forward-Looking Statements

In addition to historical information, this press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include both implied and express statements regarding the Company's overall condition and growth prospects, plans and anticipated financial results for the remainder of 2014, the strength of the Company's core recovery audit business, and the long term business objectives for the Company. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from the historical results or from any results expressed or implied by such forward-looking statements. Risks that could affect the Company's future performance include revenue that does not meet expectations or justify costs incurred, the Company's ability to develop material sources of new revenue in addition to revenue from its core recovery audit services, changes in the market for the Company's services, the Company's ability to retain and attract qualified personnel, changes to Medicare and Medicaid recovery audit contractor programs and the effects of the Company's decision to withdraw from the Medicare RAC rebid process, the Company's ability to integrate recent and future acquisitions, uncertainty in the credit markets, the Company's ability to maintain compliance with its financial covenants, client bankruptcies, loss of major clients, and other risks generally applicable to the Company's business. For a discussion of other risk factors that may impact the Company's business, please see the Company's filings with the Securities and Exchange Commission, including its Form 10-K filed on March 14, 2014. The Company disclaims any obligation or duty to update or modify these forward-looking statements.

Non-GAAP Financial Measures

EBIT, EBITDA and Adjusted EBITDA are all "non-GAAP financial measures" presented as supplemental measures of the Company's performance. They are not presented in accordance with accounting principles generally accepted in the United States, or GAAP. The Company believes these measures provide additional meaningful information in evaluating its performance over time, and that the rating agencies and a number of lenders use EBITDA and similar measures for similar purposes. In addition, a measure similar to Adjusted EBITDA is used in the restrictive covenants contained in the Company's secured credit facility. However, EBIT, EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of the Company's results as reported under GAAP. In addition, in evaluating EBIT, EBITDA and Adjusted EBITDA, you should be aware that, as described above, the adjustments may vary from period to period and in the future the Company will incur expenses such as those used in calculating these measures. The Company's presentation of these measures should not be construed as an inference that future results will be unaffected by unusual or nonrecurring items. Schedule 3 to this press release provides a reconciliation of net income (loss) to each of EBIT, EBITDA and Adjusted EBITDA.
SCHEDULE 1
PRGX Global, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Amounts in thousands, except per share data)
(Unaudited)
         
         
  Three Months Nine Months
  Ended September 30, Ended September 30,
  2014 2013 2014 2013
         
Revenue  $ 42,988  $ 53,403  $122,870  $148,709
Operating expenses:        
Cost of revenue  28,681  31,803  87,457  95,863
Selling, general and administrative expenses  10,492  13,017  31,505  35,226
Depreciation of property and equipment  1,428  2,034  4,696  6,069
Amortization of intangible assets  895  1,204  2,700  3,812
Total operating expenses  41,496  48,058  126,358  140,970
         
Operating income (loss)  1,492  5,345  (3,488)  7,739
         
Foreign currency transaction (gains) losses on short-term intercompany balances  1,221  (636)  1,073  (54)
Interest expense (income), net (44) 75 33 (89)
Income (loss) before income taxes  315  5,906  (4,528)  7,882
         
Income tax expense  554  1,029  853  1,671
         
Net income (loss)  $ (239)  $ 4,877  $ (5,381)  $ 6,211
         
         
Basic earnings (loss) per common share  $ (0.01)  $ 0.17  $ (0.18)  $ 0.21
         
Diluted earnings (loss) per common share  $ (0.01)  $ 0.16  $ (0.18)  $ 0.21
         
Weighted average common shares outstanding:        
Basic  27,744  29,396  29,203  29,075
Diluted  27,744  29,815  29,203  29,517
 
SCHEDULE 2
PRGX Global, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Amounts in thousands)
(Unaudited)
     
     
  September 30, December 31,
  2014 2013
     
ASSETS
Current assets:    
Cash and cash equivalents  $ 26,293  $ 43,700
Restricted cash  121  57
Receivables:    
Contract receivables, net  32,660  38,079
Employee advances and miscellaneous receivables, net  1,343  2,242
Total receivables  34,003  40,321
     
Prepaid expenses and other current assets  4,591  3,917
Total current assets  65,008  87,995
     
Property and equipment, net  12,771  13,994
Goodwill  13,667  13,686
Intangible assets, net  10,862  13,582
Deferred income taxes  1,991  1,701
Other assets  1,530  1,871
 Total assets   $ 105,829  $ 132,829
     
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:    
Accounts payable and accrued expenses  $ 7,720  $ 10,809
Accrued payroll and related expenses  14,776  15,415
Refund liabilities and deferred revenue  6,824  8,109
Business acquisition obligations  --   3,156
Total current liabilities  29,320  37,489
     
Other long-term liabilities  1,404  1,512
Total liabilities  30,724  39,001
     
Shareholders' equity:    
Common stock  273  294
Additional paid-in capital  591,597  604,806
Accumulated deficit  (518,767)  (513,386)
Accumulated other comprehensive income  2,002  2,114
Total shareholders' equity  75,105  93,828
     
 Total liabilities and shareholders' equity   $ 105,829  $ 132,829
         
SCHEDULE 3
PRGX Global, Inc. and Subsidiaries
Reconciliation of Net Income (Loss) to EBIT, EBITDA and Adjusted EBITDA
(Amounts in thousands)
(Unaudited)
         
         
  Three Months Nine Months
  Ended September 30, Ended September 30,
  2014 2013 2014 2013
         
Reconciliation of net income (loss) to EBIT, EBITDA and Adjusted EBITDA:        
         
Net income (loss)  $ (239)  $ 4,877  $ (5,381)  $ 6,211
         
Income tax expense  554  1,029  853  1,671
Interest expense (income), net  (44)  75  (33)  (89)
         
EBIT  271  5,981  (4,561)  7,793
         
Depreciation of property and equipment  1,428  2,034  4,696  6,069
Amortization of intangible assets  895  1,204  2,700  3,812
         
EBITDA  2,594  9,219  2,835  17,674
         
Foreign currency transaction (gains) losses on short-term intercompany balances  1,221  (636)  1,073  (54)
Acquisition-related charges  --   706  249  231
Transformation severance and related expenses  413  161  2,352  778
Stock-based compensation  1,405  1,304  3,409  3,777
         
Adjusted EBITDA  $ 5,633  $ 10,754  $ 9,918  $ 22,406
         
EBIT, EBITDA and Adjusted EBITDA are all "non-GAAP financial measures" presented as supplemental measures of our performance. They are not presented in accordance with accounting principles generally accepted in the United States, or GAAP. The Company believes these measures provide additional meaningful information in evaluating the Company's performance over time, and that the rating agencies and a number of lenders use EBIT, EBITDA and similar measures for similar purposes. In addition, a measure similar to Adjusted EBITDA is used in the restrictive covenants contained in the Company's secured credit facility. However, EBIT, EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as substitutes for analysis of our results as reported under GAAP. In addition, in evaluating EBIT, EBITDA and Adjusted EBITDA, you should be aware that in the future we will incur expenses such as those used in calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
         
SCHEDULE 4
PRGX Global, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
(Unaudited)
         
         
  Three Months Nine Months
  Ended September 30, Ended September 30,
  2014 2013 2014 2013
Cash flows from operating activities:        
Net income (loss)  $ (239)  $ 4,877  $ (5,381)  $ 6,211
Adjustments to reconcile net income (loss) to net cash provided by operating activities:        
Depreciation and amortization  2,323  3,238  7,396  9,881
Amortization of deferred debt costs  28  46  67  137
Stock-based compensation expense  1,405  1,304  3,409  3,777
Foreign currency transaction (gains) losses on short-term intercompany balances  1,221  (636)  1,073  (54)
Decrease (increase) in receivables  (2,573)  1,665  5,159  1,921
Increase (decrease) in accounts payable, accrued payroll and other accrued expenses  (987)  1,897  (4,639)  (10,213)
Other, primarily changes in assets and liabilities  100  1,037  46  (1,365)
Net cash provided by operating activities  1,278  13,428  7,130  10,295
         
Cash flows from investing activities:        
Purchases of property and equipment, net of disposals  (1,241)  (1,555)  (3,574)  (4,544)
Net cash used in investing activities  (1,241)  (1,555)  (3,574)  (4,544)
         
Cash flows from financing activities:        
Net proceeds from issuance of common stock  --   --   --   4,118
Repurchase of common stock  (9,002)  --   (20,000)  -- 
Other, net  142  (838)  (90)  (4,784)
Net cash used in financing activities  (8,860)  (838)  (20,090)  (666)
         
Effect of exchange rates on cash and cash equivalents  (1,251)  270  (873)  (484)
         
Net (decrease) increase in cash and cash equivalents  (10,074)  11,305  (17,407)  4,601
         
Cash and cash equivalents at beginning of period  36,367  31,102  43,700  37,806
         
Cash and cash equivalents at end of period  $ 26,293  $ 42,407  $ 26,293  $ 42,407
             
SCHEDULE 5
PRGX Global, Inc. and Subsidiaries
Results by Operating Segment *
(Amounts in thousands)
(Unaudited)
             
             
  Three Months Ended Nine Months Ended
  September 30, September 30,
             
  2014 2013 Change 2014 2013 Change
Revenue            
Recovery Audit Services - Americas  $ 28,550  $ 32,365  $ (3,815)  $ 80,377  $ 87,999  $ (7,622)
Recovery Audit Services - Europe/Asia-Pacific  10,708  12,009  (1,301)  32,792  33,796  (1,004)
Adjacent Services  3,586  3,625  (39)  8,150  10,705  (2,555)
Healthcare Claims Recovery Audit Services  144  5,404  (5,260)  1,551  16,209  (14,658)
Total  $ 42,988  $ 53,403  $ (10,415)  $ 122,870  $ 148,709  $ (25,839)
             
Cost of revenue            
Recovery Audit Services - Americas  $ 17,074  $ 16,920  $ (154)  $ 50,148  $ 49,255  $ (893)
Recovery Audit Services - Europe/Asia-Pacific  7,608  8,423  815  23,698  26,203  2,505
Adjacent Services  3,284  2,907  (377)  9,168  9,181  13
Healthcare Claims Recovery Audit Services  715  3,553  2,838  4,443  11,224  6,781
Total  $ 28,681  $ 31,803  $ 3,122  $ 87,457  $ 95,863  $ 8,406
             
Selling, general and administrative expenses            
Recovery Audit Services - Americas  $ 2,502  $ 3,995  $ 1,493  $ 8,320  $ 10,726  $ 2,406
Recovery Audit Services - Europe/Asia-Pacific  1,610  1,726  116  5,350  3,905  (1,445)
Adjacent Services  326  719  393  1,838  2,499  661
Healthcare Claims Recovery Audit Services  540  901  361  1,717  2,416  699
Corporate  5,514  5,676  162  14,280  15,680  1,400
Total  $ 10,492  $ 13,017  $ 2,525  $ 31,505  $ 35,226  $ 3,721
             
Depreciation of property and equipment            
Recovery Audit Services - Americas  $ 1,111  $ 1,414  $ 303  $ 3,612  $ 4,138  $ 526
Recovery Audit Services - Europe/Asia-Pacific  150  124  (26)  445  362  (83)
Adjacent Services  145  167  22  463  476  13
Healthcare Claims Recovery Audit Services  22  329  307  176  1,093  917
Total  $ 1,428  $ 2,034  $ 606  $ 4,696  $ 6,069  $ 1,373
             
Amortization of intangible assets            
Recovery Audit Services - Americas  $ 500  $ 698  $ 198  $ 1,501  $ 2,094  $ 593
Recovery Audit Services - Europe/Asia-Pacific  299  323  24  911  1,171  260
Adjacent Services  96  183  87  288  547  259
Total  $ 895  $ 1,204  $ 309  $ 2,700  $ 3,812  $ 1,112
             
Operating income (loss)            
Recovery Audit Services - Americas  $ 7,363  $ 9,338  $ (1,975)  $ 16,796  $ 21,786  $ (4,990)
Recovery Audit Services - Europe/Asia-Pacific  1,041  1,413  (372)  2,388  2,155  233
Adjacent Services  (265)  (351)  86  (3,607)  (1,998)  (1,609)
Healthcare Claims Recovery Audit Services  (1,133)  621  (1,754)  (4,785)  1,476  (6,261)
Corporate  (5,514)  (5,676)  162  (14,280)  (15,680)  1,400
Total  $ 1,492  $ 5,345  $ (3,853)  $ (3,488)  $ 7,739  $ (11,227)
             
Adjusted EBITDA            
Recovery Audit Services - Americas  $ 9,018  $ 12,132  $ (3,114)  $ 22,419  $ 29,105  $ (6,686)
Recovery Audit Services - Europe/Asia-Pacific  1,497  1,916  (419)  4,313  3,381  932
Adjacent Services  (6)  124  (130)  (2,211)  (750)  (1,461)
Healthcare Claims Recovery Audit Services  (1,085)  954  (2,039)  (4,178)  2,573  (6,751)
Corporate  (3,791)  (4,372)  581  (10,425)  (11,903)  1,478
Total  $ 5,633  $ 10,754  $ (5,121)  $ 9,918  $ 22,406  $ (12,488)
             
* The Recovery Audit Services - Americas segment represents recovery audit services, excluding Healthcare Claims Recovery Audit Services, provided in the United States, Canada and Latin America. The Recovery Audit Services - Europe/Asia-Pacific segment represents recovery audit services, excluding Healthcare Claims Recovery Audit Services, provided in Europe, Asia and the Pacific region. The Adjacent Services segment (formerly known as Profit Optimization services) represents financial advisory services and business analytics services. The Healthcare Claims Recovery Audit Services segment represents recovery audit services for healthcare claims, which consist primarily of services provided under subcontracts related to the Medicare Recovery Audit Contractor program.
CONTACT: PRGX Global, Inc.         investor-relations@prgx.com         Phone: 770-779-3011

PRGX Global, Inc. Logo